title: Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.
abstract: BACKGROUND
  Data characterising long-term survivors (LTS) with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) are limited. This analysis describes LTS using registHER observational study data.
  
  
  METHODS
  A latent class modelling (LCM) approach was used to identify distinct homogenous patient groups (or classes) based on progression-free survival (PFS), overall survival, and complete response. Demographics, clinicopathologic factors, first-line treatment patterns, and clinical outcomes were described for each class. Class-associated factors were evaluated using logistic regression analysis.
  
  
  RESULTS
  LCM identified two survivor groups labelled as LTS (n=244) and short-term survivors (STS; n=757). Baseline characteristics were similar between groups, although LTS were more likely to be white (83.6% vs 77.8%) with oestrogen receptor-positive (ER+) or progesterone receptor-positive (PgR+) disease (59.4% vs 50.9%). Median PFS in LTS was 37.2 (95% confidence interval (CI): 32.9-40.5) vs 7.3 months (95% CI: 6.8-8.0) in STS. Factors associated with long-term survival included ER+ or PgR+ disease, metastasis to node/local sites, first-line trastuzumab use, and first-line taxane use.
  
  
  CONCLUSIONS
  Prognostic variables identified by LCM define a HER2-positive MBC patient profile and therapies that may be associated with more favourable long-term outcomes, enabling treatment selection appropriate to the patient's disease characteristics.
authors.affiliation: Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 250 25th Avenue N, Ste 100 Nashville, TN 37203, USA.
authors.forename: D A
authors.initials: DA
authors.lastname: Yardley
authors.affiliation: Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA.
authors.forename: D
authors.initials: D
authors.lastname: Tripathy
authors.affiliation: University of Pittsburgh Cancer Institute, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
authors.forename: A M
authors.initials: AM
authors.lastname: Brufsky
authors.affiliation: University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, San Francisco, CA 94115, USA.
authors.forename: H S
authors.initials: HS
authors.lastname: Rugo
authors.affiliation: Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, One Medical Center Dr, Lebanon, NH 03756, USA.
authors.forename: P A
authors.initials: PA
authors.lastname: Kaufman
authors.affiliation: AdvancedBC.org 250 West 82 Street, #42, New York, NY 10024, USA.
authors.forename: M
authors.initials: M
authors.lastname: Mayer
authors.affiliation: Statistical Innovations Inc, 375 Concord Avenue, Belmont, MA 02478, USA.
authors.forename: J
authors.initials: J
authors.lastname: Magidson
authors.affiliation: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
authors.forename: B
authors.initials: B
authors.lastname: Yoo
authors.affiliation: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
authors.forename: C
authors.initials: C
authors.lastname: Quah
authors.affiliation: 1] EpiSource, LLC, 53 Fenwick Road, Waban, MA 02468, USA [2] Boston University School of Medicine, 72 East Concord Street, Boston, MA 02118, USA.
authors.forename: M
authors.initials: M
authors.lastname: Ulcickas Yood
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018567:Breast Neoplasms, Male / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D064887:Observational Studies as Topic; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D012042:Registries; D017741:Survivors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
references.citation: Cancer Treat Rev. 2012 Aug;38(5):494-504
references.pmid: 22305205
references.citation: Br J Cancer. 2010 Aug 24;103(5):607-12
references.pmid: 20664586
references.citation: Oncologist. 2005 Jan;10(1):1-14
references.pmid: 15632248
references.citation: J Clin Oncol. 2006 Dec 20;24(36):5658-63
references.pmid: 17102066
references.citation: Lancet Oncol. 2012 Nov;13(11):1105-13
references.pmid: 23059047
references.citation: Breast. 2013 Aug;22(4):525-31
references.pmid: 23352568
references.citation: Breast Cancer Res Treat. 2011 Jun;127(3):729-38
references.pmid: 21076864
references.citation: Ann Oncol. 2006 Jun;17(6):935-44
references.pmid: 16603601
references.citation: Breast Cancer. 2012 Jul;19(3):218-37
references.pmid: 22532161
references.citation: Adv Ther. 2009 Jul;26 Suppl 1:S18-26
references.pmid: 19669638
references.citation: N Engl J Med. 2012 Jan 12;366(2):109-19
references.pmid: 22149875
references.citation: N Engl J Med. 2006 Dec 28;355(26):2733-43
references.pmid: 17192538
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: J Natl Cancer Inst. 2012 Mar 7;104(5):406-14
references.pmid: 22250182
references.citation: Cancer Res. 2006 Sep 1;66(17):8327-30
references.pmid: 16951137
references.citation: Nat Rev Clin Oncol. 2010 Feb;7(2):98-107
references.pmid: 20027191
references.citation: Ann Oncol. 2010 Nov;21(11):2169-2174
references.pmid: 20427349
references.citation: Int J Cancer. 1991 Nov 11;49(5):650-5
references.pmid: 1682277
references.citation: Breast Cancer Res Treat. 2014 Jun;145(3):725-34
references.pmid: 24706168
references.citation: Asian Pac J Cancer Prev. 2012;13(4):1197-201
references.pmid: 22799305
references.citation: Ann Oncol. 2012 Aug;23(8):2034-2042
references.pmid: 22172323
references.citation: Ann Oncol. 2008 Dec;19(12):2012-9
references.pmid: 18641006
references.citation: Expert Rev Anticancer Ther. 2011 Feb;11(2):263-75
references.pmid: 21342044
references.citation: Cancer. 2011 Jul 15;117(14):3242-51
references.pmid: 21264829
references.citation: Lancet Oncol. 2013 May;14(6):461-71
references.pmid: 23602601
references.citation: J Clin Oncol. 2009 Nov 1;27(31):5278-86
references.pmid: 19770385
references.citation: JPEN J Parenter Enteral Nutr. 2003 Jan-Feb;27(1):10-5
references.pmid: 12549592
references.citation: J Clin Oncol. 2010 Jan 1;28(1):92-8
references.pmid: 19933921
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3271-7
references.pmid: 20498394
references.citation: Breast Cancer Res Treat. 2013 Oct;141(3):461-70
references.pmid: 24062208
references.citation: Clin Cancer Res. 2011 Jul 15;17(14):4834-43
references.pmid: 21768129
references.citation: N Engl J Med. 2012 Nov 8;367(19):1783-91
references.pmid: 23020162
references.citation: Clin Cancer Res. 2010 Aug 15;16(16):4226-35
references.pmid: 20664024
references.citation: N Engl J Med. 2005 Oct 20;353(16):1659-72
references.pmid: 16236737
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: J Clin Oncol. 1996 Aug;14(8):2197-205
references.pmid: 8708708
references.citation: Cancer Treat Rev. 2012 Oct;38(6):698-707
references.pmid: 22178455
references.citation: Br J Cancer. 2005 Sep 5;93(5):552-6
references.pmid: 16106267
references.citation: Oncologist. 2009 Apr;14(4):320-68
references.pmid: 19346299
references.citation: Breast Cancer Res Treat. 2012 Oct;135(3):875-83
references.pmid: 22923238
references.citation: N Engl J Med. 2005 Oct 20;353(16):1673-84
references.pmid: 16236738
references.citation: JAMA. 2006 Jun 7;295(21):2492-502
references.pmid: 16757721
references.citation: N Engl J Med. 2011 Oct 6;365(14):1273-83
references.pmid: 21991949
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: J Clin Oncol. 1999 Sep;17(9):2639-48
references.pmid: 10561337
references.citation: Clin Med Res. 2009 Jun;7(1-2):4-13
references.pmid: 19574486